Expert Insights


KRAS G12C Now Actionable With New FDA-Approved Therapy

Forty-five percent of patients with non-small cell lung cancer (NSCLC) now have actionable driver mutations. KRAS is the most frequently-mutated oncogene in human cancers, and of all KRAS driver-mutations, KRAS G12C is the most ...

A New Standard of Care

Targeted cancer therapies are prolonging patient survival times and improving quality of life, outcomes which are facilitated by tumor mutation profiling. Because cancer genomes are complex, comprehensive genomic profiling ...

Precise and Rapid Advanced Cancer Treatment Selection

For patients diagnosed with late-stage cancer, the longer treatment is delayed, the poorer the clinical prognosis, yet capturing a comprehensive picture of the disease is essential for determining the most appropriate first-line treatment ...